J. Goldman & Co’s Vanda Pharmaceuticals VNDA Stock Holding History

J. Goldman & Co’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-115,000	Closed	-$2.64M	–	315
2018 Q3	$2.64M	Buy	+115,000	New	+$2.35M	0.18%	134
2015 Q4	–	Sell	-270,000	Closed	-$3.05M	–	305
2015 Q3	$3.05M	Buy	270,000 +90,000	+50%	+$1.1M	0.26%	117
2015 Q2	$2.28M	Buy	+180,000	New	+$1.94M	0.14%	155
2015 Q1	–	Sell	-197,500	Closed	-$2.83M	–	312
2014 Q4	$2.83M	Buy	197,500 +110,000	+126%	+$1.3M	0.33%	90
2014 Q3	$908K	Hold	87,500	–	–	0.05%	223
2014 Q2	$1.42M	Buy	+87,500	New	+$1.17M	0.1%	169
2014 Q1	–	Sell	-15,000	Closed	-$186K	–	303
2013 Q4	$186K	Sell	15,000 -52,500	-78%	-$527K	0.02%	200
2013 Q3	$739K	Sell	67,500 -72,500	-52%	-$775K	0.07%	219
2013 Q2	$1.13M	Buy	+140,000	New	+$943K	0.12%	179

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

J. Goldman & Co's VNDA Position: Q3 2018 in Review

J. Goldman & Co sold out of Vanda Pharmaceuticals (VNDA) in Q3 2018, closing a stake of 140,647 shares — an estimated $2.87M sold.

J. Goldman & Co first reported a position in VNDA in Q2 2013 and held it in 14 quarters. The position peaked at $10.1M in Q3 2014. 160 funds tracked by Wall St. Rank hold VNDA as of Q3 2018.

J. Goldman & Co reported no remaining Vanda Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
J. Goldman & Co sold 140,647 Vanda Pharmaceuticals shares in Q3 2018, an estimated $2.87M.
J. Goldman & Co first reported a position in Vanda Pharmaceuticals in Q2 2013 and held it in 14 quarters.
J. Goldman & Co's Vanda Pharmaceuticals position peaked at $10.1M in Q3 2014.
160 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2018.

Based on J. Goldman & Co's 13F filing for Q3 2018, filed 14 Nov 2018.